Skip to main content
TipRanks
Go Ultimate75% OFF

Inmune Bio (0Y2) Q3 2026 Earnings Report

0 Followers

DE:0Y2 Q3 2026 EPS Results

Actual EPS
-EUR 0.15
Consensus EPS
-EUR 0.13
Beat/Miss
Missed by -EUR 0.02
One Year Ago EPS
-EUR 0.22

DE:0Y2 Q3 2026 Revenue Results

Actual Revenue
EUR 0
Expected Revenue
EUR 0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
DE:0Y2 Upcoming Earnings

Inmune Bio's next earnings date is estimated for March 4, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:0Y2 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:0.00%|
Earnings Call Sentiment|Positive

The call was strongly positive, with management highlighting progress toward the planned UK marketing application, favorable regulatory alignment, manufacturing readiness, international access infrastructure, improved financial results, and sufficient cash to fund operations through Q3 2027. The main cautions were that regulatory approval and revenue timing remain uncertain, the XPro program is still at the indication-selection stage, and the CORDStrom patent has not yet been issued.

Company Guidance

Management said it remains on track to complete a UK marketing authorization application in early February 2027, with potential UK approval by the middle of the year, is targeting a U. S. Application mid-27 subject to feedback on its planned FDA interaction, and is prioritizing The US application ahead of an EMA submission; MHRA feedback is anticipated within 3 to 6 months following submission, subject to application validation, agency review, and any request for additional information, with potential UK approval in mid 27 and the revised strategy potentially advancing approval by 6 to 12 weeks. The UK market has identified around 100 patients eligible upon approval, Approximately 40 of these 100 children will be treated in the phase 3 trial, which goes on until mid 28, and demand for off label use is anticipated among between 500 and 600 patients with non recessive but dystrophic EB; the confirmatory phase 3 trial is expected to open in Q1 next year, reimbursement discussions will begin early in 2027, and the company believes its cash is sufficient to fund operations through Q3 of 27. Management said it intends to defer any significant company funded investment in the new Xpro development program until after Ebstracel approval and is not announcing a revenue forecast or a date for first sales.

  • Ebstracel Regulatory Submission Remains on TrackINmune Bio remains on track to complete a UK marketing authorization application in early February 2027, with potential UK approval by the middle of 2027. The company is also targeting a U.S. application in mid-2027, subject to feedback from its planned FDA interaction, and is prioritizing the U.S. application ahead of an EMA submission.
  • Positive MHRA Alignment and Pre-MAA ProgressThe MHRA provided written alignment across the clinical, nonclinical, and manufacturing elements of the planned application and approved Ebstracel's pediatric investigation plan. The company submitted its final pre-MAA package on October 20, 2026, with the full application planned for early February 2027.
  • Potentially Accelerated UK Approval TimelineThe revised strategy of submitting the full data package together could advance potential UK approval by between 6 to 12 weeks compared with the company's previous expectations under a rolling review process. The company anticipates an MHRA response within 3 to 6 months following submission, subject to application validation, agency review, and any request for additional information.
  • Ebstracel Clinical and Patient Need PositioningManagement stated that the clinical data presents a compelling case for Ebstracel as a potentially first in class systemic treatment in RDEB, addressing itch, pain, inflammation, and wounds. The trial was completed at Great Ormond Street Hospital and Birmingham Children's Hospital, the two leading centers treating RDEB patients, and nearly all trial patients are currently waiting to enroll in the confirmation trial.
  • Identified UK Patient PopulationThe company's most recent assessment identified around 100 patients in the UK who would be eligible for Ebstracel upon approval. Approximately 40 of these 100 children will be treated in the phase 3 trial, which continues until mid-2028 and will require ongoing treatment thereafter.
  • Manufacturing Readiness and Quality ValidationINmune Bio stated that Ebstracel has been manufactured consistently and released against appropriate quality standards. Its pooling approach has been validated as providing reproducible batches from 3 independent master cell banks, each selected for the ability to treat RDEB. The company has begun transitioning to manufacturing scale for the commercial supply chain, with validation planned through initial batches for the confirmatory phase 3 trial opening in Q1 2027.
  • International Supply InfrastructureThe company established access to umbilical cord tissue through the Anthony Nolan UK Cord Blood Bank, with the tissues usable for manufacturing products for the United States under an agreement with Eurofins. INmune Bio stated that tissue supply, manufacturing processes, and quality controls are in place to support the transition from clinical development to reliable patient supply for a global need.
  • Uniphar Agreement Supports Patient AccessThe Uniphar agreement provides a framework to pursue named patient access in selected European, Middle Eastern, and North African markets, with the ability to expand the relationship by agreement. Where local rules permit, physicians may be able to request Ebstracel before local marketing approval or broad commercial availability.
  • Potential Early Revenue Route Through Named Patient SupplyManagement stated that named patient supplies could provide an earlier source of revenue while the company awaits separate approvals and full commercial launches in individual countries. Uniphar's sales and distribution network may allow INmune Bio to pursue these opportunities without building a complete commercial organization country by country.
  • U.S. Regulatory PreparationINmune Bio commissioned a company with rare-disease regulatory expertise to prepare a Type B meeting request for early 2027. Feedback from the FDA is expected to inform the timing of a 2027 BLA submission for accelerated approval of Ebstracel for RDEB in the United States.
  • XPro Development Strategy and Data Analysis CollaborationThe company plans to use optimization artificial intelligence, conventional analytics, preclinical research, clinical-trial data, and public biomedical information to identify diseases, patient populations, and biomarkers that warrant further investigation for XPro. The objective is to identify a rare-disease program that could support a smaller, faster, and more capital efficient development program and potentially qualify for an FDA Priority Review Voucher.
  • Disciplined Capital AllocationINmune Bio intends to defer any significant company-funded investment in a new XPro development program until after Ebstracel approval, while continuing indication selection, analysis, and partnership discussions. Management said this approach preserves XPro's potential while concentrating resources on Ebstracel, the company's closest asset to commercialization.
  • Improved Quarterly Financial ResultsNet loss attributable to common stockholders was approximately $4.7 million for the quarter ended September 30, 2026, compared with approximately $6.5 million in the prior-year quarter, a decrease of approximately 28%. Research and development expenses declined to approximately $3.2 million from $4.9 million, a decrease of approximately 35%, while general and administrative expenses declined to approximately $1.8 million from $2.5 million, a decrease of approximately 28%.
  • Cash Resources and FinancingThe company had approximately $16.3 million in cash and cash equivalents as of September 30, 2026, and raised approximately $4.5 million in gross proceeds during October from the sale of common stock and warrants to an investor. Based on its current operating plan, management believes cash is sufficient to fund operations through Q3 2027. The company also received approximately $4.2 million through Australia's R&D rebate program in July, following approximately $400 thousand from the UK in June.
  • Commercial and Strategic ReadinessManagement described Ebstracel as approaching milestones that could change INmune Bio's financial and strategic position and stated that the company is preparing for patient access, distribution, and a sustainable commercial business. The company cited a defined plan, an experienced team, and growing commercial infrastructure around its lead program.

DE:0Y2 Earnings History

DE:0Y2 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 04, 20272026 (Q4)-0.19--0.18――
Nov 05, 20262026 (Q3)-0.13-0.15-0.2229.17% (+0.06)
Aug 06, 20262026 (Q2)-0.19-0.05-0.9595.24% (+0.90)
May 07, 20262026 (Q1)-0.22-0.18-0.3953.49% (+0.21)
Mar 30, 20262025 (Q4)-0.24-0.18-0.3650.50% (+0.18)
Oct 30, 20252025 (Q3)-0.29-0.22-0.5460.00% (+0.33)
Aug 07, 20252025 (Q2)-0.35-0.95-0.45-110.00% (-0.50)
May 08, 20252025 (Q1)-0.43-0.39-0.5529.51% (+0.16)
Mar 27, 20252024 (Q4)-0.50-0.36-0.4214.89% (+0.06)
Oct 31, 20242024 (Q3)-0.46-0.54-0.43-25.00% (-0.11)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed